Cytori Therapeutics Inc (NASDAQ:CYTX) hit a new 52-week low on Friday . The stock traded as low as $1.45 and last traded at $1.45, with a volume of 122787 shares. The stock had previously closed at $1.67.
CYTX has been the subject of several recent analyst reports. Zacks Investment Research downgraded Cytori Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, March 8th. Maxim Group set a $20.00 price target on Cytori Therapeutics and gave the stock a “buy” rating in a report on Monday, April 30th. B. Riley raised Cytori Therapeutics from a “neutral” rating to a “buy” rating in a report on Friday, March 9th. ValuEngine raised Cytori Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Finally, HC Wainwright set a $40.00 price target on Cytori Therapeutics and gave the stock a “buy” rating in a report on Monday, May 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $22.25.
The firm has a market capitalization of $10.29 million, a P/E ratio of -0.22 and a beta of 3.11.
Cytori Therapeutics (NASDAQ:CYTX) last released its earnings results on Thursday, May 10th. The biotechnology company reported ($0.70) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.30). Cytori Therapeutics had a negative return on equity of 190.35% and a negative net margin of 428.14%. The firm had revenue of $0.73 million for the quarter, compared to analyst estimates of $2.43 million. During the same period last year, the firm earned ($2.40) EPS. analysts anticipate that Cytori Therapeutics Inc will post -1.74 EPS for the current year.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.